Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Open-Label Dose Escalation Study of AMG 479 in Japanese Adults With Advanced Solid Tumors
jRCT2080221129Phase 1
- Sponsor
- Takeda
- Start
- Jun 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ganitumab in Nonhematologic neoplasms, sponsored by Takeda. Primary endpoints: Safety and tolerability of AMG 479 and Pharmacokinetics of AMG 479.
02
Drugs
ganitumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080221129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221129.